Head to Head Comparison: Seres Therapeutics (MCRB) and Its Competitors

Seres Therapeutics (NASDAQ:MCRB) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Seres Therapeutics to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, dividends, risk, profitability and valuation.

Valuation & Earnings

This table compares Seres Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seres Therapeutics	$1.88 million	$5.70 million	-0.86
Seres Therapeutics Competitors	$727.61 million	$12.25 million	-10.38

Seres Therapeutics’ rivals have higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Seres Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1	1	2	0	2.25
Seres Therapeutics Competitors	9791	15070	45345	1572	2.54

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 713.40%. As a group, “Biotechnology” companies have a potential upside of 93.57%. Given Seres Therapeutics’ higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than its rivals.

Profitability

This table compares Seres Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Seres Therapeutics Competitors	-9,051.23%	-201.20%	-30.64%

Risk & Volatility

Seres Therapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Seres Therapeutics’ rivals have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Summary

Seres Therapeutics rivals beat Seres Therapeutics on 8 of the 13 factors compared.

About Seres Therapeutics

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.